Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults

Trial Profile

Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs SP 0173 (Primary) ; Diphtheria tetanus and pertussis vaccine
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 28 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 17 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 Apr 2016 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top